News | Pulmonary Embolism | February 16, 2022

Inari Medical Announces First Patient Enrolled in the PEERLESS Trial

Randomized controlled trial will evaluate outcomes of the FlowTriever system in pulmonary embolism patients.

Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a prospective, randomized controlled trial comparing the outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the FlowTriever system versus catheter-directed thrombolysis (CDT).

The FlowTriever system


February 16, 2022 – Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a prospective, randomized controlled trial comparing the outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the FlowTriever system versus catheter-directed thrombolysis (CDT).

The first PEERLESS patient was enrolled by Dr. Amir Kaki, Interventional Cardiologist, Ascension St. John Hospital in Michigan. PEERLESS will randomize 550 patients and will also enroll up to 150 patients in a registry cohort for patients who cannot be randomized due to an absolute contraindication to thrombolytics. The trial will include up to 60 centers in the United States and Europe.

“We are excited and honored to enroll the first patient in this landmark clinical trial,” said Kaki. “From our own experience, the FlowTriever system has the potential to change the way we treat PE patients, safely removing significant clot burden while avoiding thrombolytics and procedure-related ICU stay. Ascension St. John’s research team continues to be on the cutting-edge of medical device research and we look forward to contributing and developing the evidence base for the treatment of pulmonary embolism.”

“The start of PEERLESS represents an exciting milestone in the advancement of PE treatment, where randomized clinical data evaluating relevant patient outcomes has been limited,” said Global Co-Principal Investigator, Dr. Carin Gonsalves, Professor of Radiology and Co-Director of the Division of Interventional Radiology at Thomas Jefferson University in Philadelphia, PA. “PEERLESS marks an opportunity to directly compare FlowTriever outcomes to CDT outcomes, addressing current gaps in our understanding of PE and providing critical information to clinicians on the optimal treatment for these patients.”

“The treatment of PE is undergoing a transformation. We have been thrilled by the desire of physicians to move this field forward and generate high-quality data through PEERLESS,” said Dr. Thomas Tu, Inari’s Chief Medical Officer. “We are grateful for the collaboration and dedication of our clinical trial investigators on this first of many PE studies to come.”

For more information: https://www.inarimedical.com/

Related Content

News | Pulmonary Embolism

February 14, 2022 — Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the ...

Home February 14, 2022
Home
News | Pulmonary Embolism

August 9, 2021 — Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative ...

Home August 09, 2021
Home
News | Pulmonary Embolism

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world ...

Home October 23, 2020
Home
News | Pulmonary Embolism

October 18, 2019 —­­ Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than ...

Home October 18, 2019
Home
News | Pulmonary Embolism

March 4, 2019 — Artificial intelligence (AI) radiology solution provider Aidoc announced the commercial release of its ...

Home March 04, 2019
Home
News | Pulmonary Embolism

October 23, 2018 — Daniel J. Schimmel, Jr., M.D., MS, a cardiologist at Northwestern Memorial Hospital, recently ...

Home October 23, 2018
Home
News | Pulmonary Embolism

June 29, 2018 — Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with ...

Home June 29, 2018
Home
News | Pulmonary Embolism

May 11, 2018 — Results of the FlowTriever Pulmonary Embolectomy (FLARE) study were presented as late-breaking clinical ...

Home May 11, 2018
Home
Technology | Pulmonary Embolism

March 1, 2017 — BTG plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance has been granted to the Ekos ...

Home March 01, 2017
Home
Feature | Pulmonary Embolism | Alain T. Drooz, M.D., FSVM, and David J. Spinosa, M.D.

Acute pulmonary embolism (PE) can pose a major treatment quandary for clinicians. While massive (high-risk) PE is ...

Home March 28, 2016
Home
Subscribe Now